Power Law company profile

Baoji Pharmaceutical

Biotech & Life Sciences · Baoshan District, China · Founded 2019 · IPO 2025 Unicorn

A biopharma R&D manufacturer, a Sino-foreign joint biopharmaceutical enterprise integrating drug R&D and production

Valuation

$876M

Market cap · May/2026

Revenue

$6.8M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

8 investors on Baoji Pharmaceutical's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 8 investors entered at this stage

Oriental Fortune Capital

SHC Shanghai Biomedical Fund

Shengshi Capital

Center Lab

Dongfang Fuhai

Haitong Innovation Capital Management

Shanghai International Group

Yuanchuang Capital

Global footprint

Where Baoji Pharmaceutical has talent and traffic

Workforce by country

🇨🇳 China · Baoshan District HQ

Book a demo for the full country breakdown

Web traffic by country

120 monthly visits
across markets

🇹🇷 Turkey83.3%

Top 1 markets shown

Market sentiment

What the market is saying about Baoji Pharmaceutical

An AI-synthesized read of the highest-engagement posts about Baoji Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Baoji Pharmaceutical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles